| Literature DB >> 28040721 |
Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, Susana M Campos, Kathleen R Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S Dizon, Oliver Dorigo, Patricia J Eifel, Christine M Fisher, Peter Frederick, David K Gaffney, Ernest Han, Susan Higgins, Warner K Huh, John R Lurain, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W Remmenga, R Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A Valea, Emily Wyse, Catheryn M Yashar, Nicole McMillian, Jillian Scavone.
Abstract
Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)-dependent and HPV-independent pathways. The NCCN Vulvar Cancer panel is an interdisciplinary group of representatives from NCCN Member Institutions consisting of specialists in gynecological oncology, medical oncology, radiation oncology, and pathology. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer provide an evidence- and consensus-based approach for the management of patients with vulvar SCC. This manuscript discusses the recommendations outlined in the NCCN Guidelines for diagnosis, staging, treatment, and follow-up.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28040721 DOI： 10.6004/jnccn.2017.0008
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908